The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma

Howard L. Kaufman, MD
Published Online:2:39 PM, Thu May 18, 2017

Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.